STAAR Surgical (NASDAQ:STAA) Receives $46.38 Consensus Price Target from Brokerages

STAAR Surgical (NASDAQ:STAA) has earned an average recommendation of “Hold” from the ten ratings firms that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $46.38.

A number of equities analysts recently weighed in on STAA shares. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a report on Thursday, April 4th. Canaccord Genuity Group increased their price objective on STAAR Surgical from $32.00 to $46.00 and gave the company a “hold” rating in a research report on Monday, April 8th. Mizuho boosted their target price on STAAR Surgical from $45.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $50.00 price target on shares of STAAR Surgical in a research note on Monday, April 1st. Finally, William Blair upgraded shares of STAAR Surgical from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 4th.

Insider Transactions at STAAR Surgical

In related news, Director Aimee S. Weisner acquired 1,750 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was bought at an average cost of $38.11 per share, for a total transaction of $66,692.50. Following the purchase, the director now owns 10,864 shares in the company, valued at approximately $414,027.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.10% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

A number of institutional investors have recently bought and sold shares of STAA. Handelsbanken Fonder AB raised its stake in STAAR Surgical by 18.0% during the 4th quarter. Handelsbanken Fonder AB now owns 10,500 shares of the medical instruments supplier’s stock valued at $328,000 after purchasing an additional 1,600 shares during the period. Defender Capital LLC. increased its holdings in shares of STAAR Surgical by 33.0% in the 4th quarter. Defender Capital LLC. now owns 722,532 shares of the medical instruments supplier’s stock worth $22,550,000 after buying an additional 179,135 shares during the last quarter. Seven Eight Capital LP lifted its holdings in shares of STAAR Surgical by 369.2% in the 3rd quarter. Seven Eight Capital LP now owns 46,167 shares of the medical instruments supplier’s stock valued at $1,855,000 after acquiring an additional 36,327 shares during the last quarter. Invesco Ltd. grew its position in STAAR Surgical by 121.6% in the third quarter. Invesco Ltd. now owns 165,661 shares of the medical instruments supplier’s stock worth $6,656,000 after acquiring an additional 90,896 shares in the last quarter. Finally, Citigroup Inc. increased its stake in STAAR Surgical by 14.5% during the third quarter. Citigroup Inc. now owns 19,163 shares of the medical instruments supplier’s stock worth $770,000 after acquiring an additional 2,434 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Stock Down 0.1 %

Shares of STAA opened at $45.51 on Wednesday. STAAR Surgical has a 52 week low of $26.66 and a 52 week high of $69.00. The stock has a market cap of $2.24 billion, a P/E ratio of 105.84 and a beta of 0.80. The business’s 50 day moving average price is $41.08 and its 200-day moving average price is $35.86.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings results on Monday, February 26th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). STAAR Surgical had a net margin of 6.62% and a return on equity of 8.73%. The company had revenue of $76.27 million for the quarter, compared to the consensus estimate of $75.94 million. During the same quarter in the previous year, the business earned $0.04 earnings per share. STAAR Surgical’s revenue was up 19.1% compared to the same quarter last year. On average, equities analysts anticipate that STAAR Surgical will post 0.03 EPS for the current year.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.